Floatz logo

L-CYSTEINE, L-CYSTEINYL-L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-LYSYLGLYCYL-L-PROLYL-L-.ALPHA.-ASPARTYL-, CYCLIC (1->9)-DISULFIDE

Recurrent Pancreatic Cancer

City of Hope Medical Centerprotein_peptidePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

330 Active assets in the Recurrent Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
S-1
Liu Xiufeng
Phase 4BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

L-CYSTEINE, L-CYSTEINYL-L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-LYSYLGLYCYL-L-PROLYL-L-.ALPHA.-ASPARTYL-, CYCLIC (1->9)-DISULFIDE is also rated in:

pancreatic acinar cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →